Abstract
A previous report from this laboratory demonstrated that the majority of phosphatidylcholine in hamster heart was formed from choline via the CDP-choline pathway (Zelinski, T. A., Savard, J. D., Man, R. Y. K., and Choy, P. C. (1980) J. Biol. Chem. 255, 11423-11428). In this study, phosphatidylcholine biosynthesis in myopathic hamster hearts was compared with date-matched controls. Upon perfusion with [Me-3H]choline, a 22% increase in labeling of phosphatidylcholine was observed in the hearts of 150-200-day-old myopathic hamsters. However, total cardiac phosphatidylcholine remained unchanged. In order to elucidate the cause for the increase in labeling of phosphatidylcholine during cardiomyopathy, the intermediates for phosphatidylcholine formation in the myopathic hearts were analyzed. The labeling and pool size of CDP-choline in the myopathic hearts were found to be 72 and 60% of the controls. This uneven reduction caused a 20% increase in the specific radioactivity of CDP-choline. Since CDP-choline is the immediate precursor for phosphatidylcholine formation, it can be concluded that the increase in labeling of phosphatidylcholine in the myopathic heart was a direct reflection on the specific radioactivity of CDP-choline. Furthermore, the net amount of phosphatidylcholine synthesized was estimated to be similar between the normal and myopathic hearts. The reduction in CDP-choline formation was probably caused by an observed decrease in CTP concentration in cardiomyopathy. However, phosphocholine cytidylyltransferase activity was elevated. The enhanced enzyme activity is regarded as one of the compensatory mechanism for the myopathic heart to maintain a minimum CDP-choline level, in order to prevent reduction of net phosphatidylcholine biosynthesis.
Highlights
Through autosomal recessive inheritance, cardiomyopathy develops spontaneously in a strain of inbred Syrian hamsters (B10 14.6 strain)
Subsequent analysis demonstrated that this increase was caused by a change in the specific radioactivity of CDP-choline in the myopathic hearts, but the net amount of phosphatidylcholine biosynthesis remained unchanged in cardiomyopathy
A previous report from this laboratory demonstrated that the majority of phosphatidylcholine in hamster heart is formed via the CDP-choline pathway [10]
Summary
The enhanced enzyme activity is regarded as one of the compensatory mechanism for the myopathic heart to maintain a minimum CDP-choline level, in order to prevent reduction of net phosphatidylcholine biosynthesis. Biochemical changes including the rate of fatty acid oxidation [4, 5], high energy phosphate levels [6], phospholipid content [7, 8], and enzyme activities [9] were reported The results from these studies indicate that phospholipid biosyn-. We compared the rate of phosphatidylcholine formation via the CDP-choline pathway in the hearts of the normal and myopathic hamsters. Subsequent analysis demonstrated that this increase was caused by a change in the specific radioactivity of CDP-choline in the myopathic hearts, but the net amount of phosphatidylcholine biosynthesis remained unchanged in cardiomyopathy
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
